Tengjun Biotechnology Corp. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 36.42 million. Net income was USD 3.43 million compared to net loss of USD 0.107302 million a year ago. Basic earnings per share from continuing operations was USD 0.04 compared to basic loss per share from continuing operations of USD 0.01 a year ago. Diluted earnings per share from continuing operations was USD 0.04 compared to diluted loss per share from continuing operations of USD 0.01 a year ago.
For the nine months, sales was USD 91.99 million. Net income was USD 7.57 million compared to net loss of USD 0.495482 million a year ago. Basic earnings per share from continuing operations was USD 0.1 compared to basic loss per share from continuing operations of USD 0.03 a year ago. Diluted earnings per share from continuing operations was USD 0.1 compared to diluted loss per share from continuing operations of USD 0.03 a year ago.